Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Asian Currencies Trade Mixed as Yen Hovers Near 40-Year Low, Dollar Holds Firm on Fed Outlook 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
SpaceX Eyes Starlink Mobile Phone Service to Challenge Verizon, AT&T, and T-Mobile 
Asian Markets Rally as Micron and Qualcomm AI Outlook Lifts Global Tech Stocks 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Morgan Stanley Sees Chinese Auto Market Recovery Gaining Momentum in Late Summer 
Malaysia Central Bank Moves to Support Ringgit Amid Foreign Fund Outflows 
Oil Prices Drop as Strait of Hormuz Shipping Recovers 
Celltrion Inc., a biopharmaceutical company headquartered in Incheon, South Korea, is merging with its Celltrion Healthcare subsidiary in an effort to strengthen its business synergy or combined effort. The biosimilar producer and its biosimilar marketing unit are set to be consolidated this year.
Seo Jung Jin, Celltrion Group’s chairman, said on Thursday, Aug. 17, that once Celltrion is incorporated with Celltrion Healthcare, the newly-formed entity will also take in Celltrion Pharma. The chairman said this integration will eventually happen later but did not provide an exact time frame. After all the mergings, Celltrion, Celltrion Healthcare, and the company’s chemical pharma producer will work together as one.
According to The Korea Times, Celltrion revealed its plan to acquire Celltrion Healthcare during the company’s recent regulatory filing. The changes will also entail the issuance of new shares of Celltrion to shareholders of Celltrion Healthcare, and the merger ratio is expected to stand at 1:0.4492620.
It was mentioned that the Celltrion chairman holds a 95% stake in Celltrion Holdings which in turn holds a 20.02% stake in Celltrion. The holdings also have a 35.54% stake in Celltrion Healthcare and a 54.96% stake in Celltrion Pharm.
"Celltrion is expected to complete the merger of Celltrion Healthcare by the end of the year, followed by the next merger with Celltrion Pharm in the next six months," Seo Jung Jin shared during an online conference.
The Celltrion Group said it will merge the mentioned companies, but the plan still needs the approval of shareholders. This may be completed on October 23 at the shareholders' meeting. Celltrion and Celltrion Healthcare will eventually be dissolved after the merger.
To date, while the merger is still being processed, The Korea Herald reported that Celltrion is focusing on producing and developing bio-pharmaceutical products while Celltrion Healthcare is working more on selling these products.
Photo by: Celltrion Press Room
